LINDSAY RHINEVAULT: Open Payments
NPI 1760191407 · ROCHESTER, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$443 in 17 payments from 8 companies in 2025. Trend: 2023 $456 · 2024 $810 · 2025 $443
Food & beverage: $443
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $142 |
| Novartis Pharmaceuticals Corporation | 3 | $68 |
| Amgen Inc. | 1 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $41 |
| Edwards Lifesciences Corporation | 1 | $34 |
| Novo Nordisk Inc | 2 | $34 |
| SCPHARMACEUTICALS INC. | 1 | $18 |
Products named: FARXIGA, LEQVIO, LOKELMA, Repatha, JARDIANCE, Wegovy, VYNDAQEL, FUROSCIX.
Industry payments across NY — which companies pay providers there.
